Defendant
1 case as defendant.
Inari Medical, Inc. is a medical device company founded in 2011 and headquartered in Irvine, California. The company operated as a publicly traded firm on the NASDAQ exchange (ticker: NARI) until it was acquired by Stryker Corporation (NYSE: SYK). The acquisition was completed on February 19, 2025, and Inari Medical now operates as a wholly owned subsidiary of Stryker. Prior to the acquisition, the company had a market capitalization of approximately $4.68 billion and reported revenues of around $493.5 million for the 2023 fiscal year.
The company develops, manufactures, and sells catheter-based mechanical thrombectomy devices for the treatment of venous diseases, particularly venous thromboembolism (VTE). Its products are designed to remove blood clots from veins and arteries without the use of thrombolytic drugs. Key product lines include the FlowTriever system for the treatment of pulmonary embolism (PE) and the ClotTriever system for deep vein thrombosis (DVT). Other products include the RevCore catheter for in-stent thrombosis and the InThrill thrombectomy system.
As a litigant, Inari Medical is an operating company asserting its own patents. Its litigation history in the provided database shows one case as a plaintiff and zero as a defendant. This case, Inari Medical, Inc. v. Imperative Care, Inc. et al., was filed in the U.S. District Court for the Northern District of California on May 22, 2024. The company's most significant recent corporate event is its acquisition by medical technology leader Stryker, which aimed to integrate Inari's VTE portfolio into its own business.
An Inter Partes Review (IPR) was filed by Unified Patents PTAB Data concerning US patent 12016580, with Inari Medical Inc. as the implicit patent owner. The case has been instituted.